abstract |
The invention concerns compounds of general formula (I), wherein R1 represents H, alkyl, cycloalkyl or cycloalkylalkyl and R2 represents H or alkyl; R3 represents H, alkyl or aralkyl; X represents a bond or a linear or branched alkylene radical (II); Y represents H, cycloalkyl, OR14, SR15, NR4R5 or A represents a bond or phenyl; B and B' are independently selected among alkyl, NR6R7, SR8 and carbocyclic aryl or heterocyclic aryl radicals with five or six members optionally substituted; R4 represents H, alkyl, aryl, cycloalkyl, cycloalkylalkyl, aralkyl, -C(O)R9, -C(O)OR9, -C(O)NHR9 or -SO2R9, or further aryl or aralkyl whereof the aromatic ring is optionally substituted and R5 represents in particular H or alkyl, or further R4 and R5 form with the nitrogen atom bearing them a non-aromatic heterocycle of five to seven members optionally substituted; R6 represents (in particular) H or alkyl and R7 represents (in particular) H or alkyl; R8 represents an alkyl radical optionally substituted; R9 represents alkyl, haloakyl, cycloalkyl or cycloalkylalkyl, or further one of the aralkyl or aryl or heteroaryl radicals optionally substituted; R14 and R15 independently represent (in particular) alkyl, phenyl or aralkyl. The compounds of general formula (I) can be used as NO synthase inhibitors and as modulators of sodium channels (for treating pains, multiple sclerosis, the central nervous system or the peripheral nervous system and the like). |